Fifty eight consecutive untreated @entity1 with locally advanced @entity2622 (LACC) received neoadjuvant chemotherapy (NACT) with @entity900 (CDDP) 80 mg/sqm (day 1) + @entity1206 (VRL) 25 mg/sqm (day 1 and 8). Three cycles of chemotherapy were planned every 21 days. Within 28 days from the completion of chemotherapy @entity1 in complete or partial response were submitted to radical hysterectomy with pelvic lymphadenectomy. On 155 cycles, hematologic @entity137 was mild (G3-4 @entity1398 and @entity417 occurred in 16% and 5%, respectively). Forty-seven @entity1 (81%) were submitted to radical surgery; eight (14%) @entity1 were deemed ineligible for surgery because of poor response to treatment, two (3%) for anesthesia contraindications and one (2%) refused surgery. At pathologic examination 12 @entity1 (25%) had a complete response, one (2%) @entity2735 , six (13%) residual microinvasive disease, and 28 (60%) a partial response. None had extracervical disease. Eight @entity1 (14%) had microscopic lymph node @entity3 . The number of cycles administered was significantly associated with a good pathologic response. Association of CDDP and VRL as NACT in LACC appears safe and effective. Low cost and modest @entity137 would support the initiation of a multicenter randomized phase III trial to compare this association with @entity900 alone.

XXXX and @entity1206 as neoadjuvant chemotherapy in locally advanced cervical cancer: a phase II study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity2735 :: ('MESH:D002278', 'Disease') :: ['in-situ carcinoma'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity2622 :: ('MESH:D002583', 'Disease') :: ['cervical carcinoma'] @entity1206 :: ('MESH:C030852', 'Chemical') :: ['vinorelbine'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']
@entity900 :: (MESH:D002945,Chemical) :: ['Cisplatin']
